We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 104 for:    pillar

Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter (PILLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02872636
Recruitment Status : Recruiting
First Posted : August 19, 2016
Last Update Posted : November 27, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The objective of this feasibility study is to demonstrate the safety and feasibility of using an investigational extracorporeal system and catheter to filter hemorrhagic cerebrospinal fluid (CSF) post subarachnoid hemorrhage (SAH) treatment, and reintroduce the CSF via the same catheter.

Condition or disease Intervention/treatment
Subarachnoid Hemorrhage Device: Spinal catheter insertion with extracorporeal filtration of CSF

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Actual Study Start Date : March 23, 2017
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Treatment Group Device: Spinal catheter insertion with extracorporeal filtration of CSF
Extracorporeal filtration of CSF


Outcome Measures

Primary Outcome Measures :
  1. Device/System Safety - Adverse events related to the filtration procedure [ Time Frame: 30 days ]
    Adverse events related to the filtration procedure

  2. Adverse events related to the system catheter insertion [ Time Frame: 30 days ]
    Nerve or tissue damage related to catheter insertion


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 18 years or older
  • Informed consent by the patient or his/her legally authorized representative
  • Modified Fisher Grade 2, 3, or 4
  • Hunt & Hess I-III
  • First aneurysmal SAH that has been confirmed by Angio, CTA or MRA
  • Patient is ≤ 48 hours post bleeding event
  • World Federation of Neurosurgeons (WFNS) Grades I-IV and those Grade V patients who improve to Grade IV or less after ventriculostomy.

Exclusion Criteria:

  • Patients with a SAH due to mycotic aneurysm or AV malformation
  • Patients who present with an acute MI or unstable angina
  • Patients with uncontrolled diabetes
  • Patients who present with a creatinine > 2.0mg/dl
  • Imaging demonstrates supratentorial mass lesions greater than 50 cc
  • Imaging demonstrates more than 5 mm of mid-line-shift associated with infarction and or edema
  • Effacement of the basilar cisterns (suprasellar, ambient, chiasmatic and quadrageminal)
  • Vasospasm on admission as defined by angiographic evidence
  • Patients with a coagulopathy that cannot be reversed per the professional discretion of the investigator
  • Thrombocytopenia def. platelet count < 100,000
  • Patients on low molecular weight heparin e.g., Lovenox
  • Patients on Clopidogrel bisulfate (Plavix) or other chronic platelet inhibitors
  • Patients with a documented history of cirrhosis
  • Patients who will be managed with supportive care rather than intervention
  • Obstructive hydrocephalus i.e., non-communicating
  • Pregnancy
  • History of posterior fusion hardware that would interfere with placement of the catheter
  • Pre-existing Lumbar Drain
  • Local skin infections or eruptions over the puncture site
  • Signs of systemic infection/sepsis or pneumonia
  • Lumbar puncture within 6 hours
  • Concurrent participation in another study which is not observational or retrospective in nature without prior approval from the Sponsor
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02872636


Contacts
Contact: Elizabeth S Scheurer 651-251-9454 lscheurer@minnetronix.com
Contact: Julie Messer 651-251-9138 jmesser@minnetronix.com

Locations
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Nonyelum Harcourt    612-624-8117    harco002@umn.edu   
Principal Investigator: Andrew W Grande, MD         
Sub-Investigator: Bharathi Jagadeesan, MD         
United States, North Carolina
Duke Universiaty Recruiting
Durham, North Carolina, United States, 27705
Contact: Kristina Balderson, CCRC    919-684-0071    Kristina.Balderson@duke.edu   
Principal Investigator: Christa B Swisher, MD         
Sub-Investigator: Erik Hauck, MD         
Sub-Investigator: L. Fernando Gonzalez, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Laura Boyden       Laura.Boyden@jefferson.edu   
Principal Investigator: Fred Rincon, M.D.         
Sub-Investigator: M. Reid Gooch, M.D.         
Sub-Investigator: Nabeel Herial, M.D.         
Sub-Investigator: Jack Jallo, M.D.         
Sub-Investigator: Pascal Jabbour, M.D.         
Sub-Investigator: Hekmat Zarzour, M.D.         
United States, Texas
University of Texas Recruiting
Houston, Texas, United States, 77030
Contact: Kanako Matsumura    713-500-6133    kanako.matsumura@uth.tmc.edu   
Principal Investigator: Spiros Blackburn, MD         
Sponsors and Collaborators
Minnetronix
Investigators
Study Director: Elizabeth S Scheurer Principal Clinical Research Scientist
More Information

Responsible Party: Minnetronix
ClinicalTrials.gov Identifier: NCT02872636     History of Changes
Other Study ID Numbers: DK-0000-001-306
First Posted: August 19, 2016    Key Record Dates
Last Update Posted: November 27, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:
Hemorrhage
Subarachnoid Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases